Novo Nordisk, a leading pharmaceutical company specializing in obesity treatment, has announced a reduction of thousands of jobs across various departments. This decision is part of a broader restructuring strategy driven by decreased sales figures within the weight-loss drug market. The company anticipates a more competitive landscape requiring adjustments to its operational model. The layoffs are impacting various teams, including research and development, sales, and marketing, as Novo Nordisk focuses on streamlining operations and optimizing profitability. The company’s financial performance is currently being closely monitored.
Credits: Al Jazeera – Breaking News, World News and Video from Al Jazeera